LivaNova 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- LivaNova reported 3rd quarter 2026 revenue of $393 million, up 10% versus the prior year, with double-digit growth across regions and strength in cardiopulmonary and epilepsy.
- Cardiopulmonary revenue was $225 million, up 11% versus the 3rd quarter of 2025; heart-lung machine revenue and cardiopulmonary consumables revenue each grew low double digits.
- Epilepsy revenue increased 11% versus the 3rd quarter of 2025, including 10% growth in the US and 14% combined growth in Europe and rest of world.
- Adjusted gross margin was 69%, adjusted operating income was $92 million versus $80 million, adjusted operating income margin was approximately 24% versus 23%, and adjusted diluted earnings per share was $1.23 versus $1.11.
- Adjusted SG&A expense was $136 million versus $123 million, primarily reflecting planned commercial and IT infrastructure investments; adjusted R&D expense was $45 million, in line with the prior-year period.
- At September 30th, cash was $563 million and total debt was $299 million; adjusted free cash flow for the quarter was $56 million versus $62 million in the prior-year period.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. As a reminder, this conference call is being recorded. I would now like to introduce you to our host for today's conference, Ms. Briana Gotlin, LivaNova's Vice President of Investor Relations.
Briana, please go ahead. Thank you, and welcome to our conference call and webcast discussing LivaNova's financial results for the third quarter of 2026.
Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and member of the Board of Directors, Alex Shvartsburg, our Chief Financial Officer, and Ahmet Tezel, our Chief Innovation Officer. Before we begin, I would like to remind you that discussions during this call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings and documents furnished to the SEC, including today's press release that is available on our website. We do not undertake to update any forward-looking statement. Also, the discussions will include certain non-GAAP financial measures with respect to performance, including but not limited to revenue results, which will be stated on a constant currency basis.
Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is available on our website. We have also posted a presentation to our website that summarizes the points of today's call. This presentation is complementary to the other call materials and should be used as an enhanced communication tool. You can find the presentation and the press release in the investor section of our website under News, Events, and Presentations at investor.livanova.com. With that, I'll turn the call over to Vlad.
Thank you, Briana, and thank you everyone for joining us today. Welcome to LivaNova's conference call for the third quarter of 2026. LivaNova delivered another quarter of double-digit revenue growth with strength across all regions, driven by commercial execution and healthy demand for our cardiopulmonary and epilepsy technologies. The core businesses continue to fuel both current performance and disciplined investment, enabling us to further strengthen our existing franchises while advancing new growth opportunities such as obstructive sleep apnea, or OSA. As we prepare to enter this attractive high-growth, high-margin market, our team is focused on building a strong foundation for long-term success in OSA. Importantly, we're not building from the ground up. We're leveraging our Neuromodulation capabilities developed through our epilepsy business, including product development expertise, established supply chain infrastructure, a global footprint, and market access competencies.
To complement these existing strengths, we have also made key hires across the OSA commercial leadership team, adding targeted expertise as we prepare for commercialization. The strength of LivaNova's capabilities supports future market access for proximal hypoglossal nerve stimulation, or pHGNS. Recently, LivaNova contributed its robust clinical evidence to the CPT code application reviewed by the AMA editorial panel. Our OSPREY randomized control trial provided level 1 evidence to support this application. We are pleased with their decision to establish new category 1 codes that will include LivaNova's technology. Subject to finalization, the new codes are expected to take effect on January 1, 2028. We believe this decision is an important development that further bolsters our ability to achieve appropriate reimbursement. We are proud to have supported efforts to improve patient access to care and look forward to leveraging these new category codes, once effective, in the commercialization of our OSA technology.
With pHGNS, we believe we have a clear right to win, supported by rigorous clinical evidence, a differentiated technology designed for a broader and more complex patient population, and leading Neuromodulation capabilities across LivaNova. For the remainder of the call, I will discuss the third quarter results and provide updated top-line guidance for 2026. After my comments, Ahmet Tezel will discuss key innovation updates, and Alex Shvartsburg will then provide additional details on our results and updated 2026 guidance. I will wrap up with closing remarks before moving on to Q&A. Now turning to segment results. For the Cardiopulmonary segment, revenue was $225 million in the quarter, an increase of 11% versus the third quarter of 2025, led by double-digit growth in both Europe and the U.S. Heart-lung machine revenue grew low double digits in the quarter, marked by quarterly record Essenz placements and sustained favorable price premiums.
Cardiopulmonary consumables revenue, which encompasses all non-HLM products in our Cardiopulmonary portfolio, grew low double digits in the quarter. This was led by strength in oxygenators and perfusion tubing kits. Improvements in third-party component availability and internal manufacturing optimization drove significant year-over-year increases in oxygenator output, supporting strong performance year to date. Oxygenator market demand continues to exceed the industry's ability to supply, which represents a significant opportunity to expand our market position. As a reminder, our three key operational initiatives to capture this opportunity are optimizing processes across our supply chain network, adding a new oxygenator production line, and strengthening the reliability of critical component supply. The operational launch of the new dedicated oxygenator manufacturing line marks another key milestone in the execution of our strategy.
Together with the Thermo Fisher component agreement announced last quarter, represents significant progress across these three initiatives and positions us to drive double-digit capacity expansion in 2027. Strong performance across our leading product lines, combined with healthy underlying global demand and operational execution, reinforces our confidence in the durability of growth in the Cardiopulmonary business. As the market leader in HLM, with a global installed base of more than 10,000 systems, and Essenz representing only about 20% of that base today, we see a significant multi-year upgrade opportunity ahead. For the full year 2026, we now expect Cardiopulmonary revenue to grow 10.5%-11.5%, up from 9.5%-10.5% previously. We continue to expect Essenz to represent approximately 80% of annual HLM units placements in 2026, up from 55% in 2025. This forecast also assumes continued market share gains in consumables as we execute on our manufacturing expansion plans.
Turning to epilepsy. Revenue increased 11% versus the third quarter of 2025, with double-digit growth across all regions. U.S. epilepsy revenue increased 10% versus the prior year period, while epilepsy revenue in the Europe and rest of world regions increased a combined 14% year-over-year. Performance was driven by volume and favorable realized price, supported by impactful clinical evidence, improved reimbursement, and sustained commercial excellence. Similar to the prior quarter, improved realized price in the third quarter benefited from reduced volume discounting, in addition to our standard annual list price increase. The long-term clinical evidence from our CORE-VNS study is strengthening physician confidence, accelerating referrals, and will support earlier adoption of VNS Therapy in the patient care pathway. At the same time, improved U.S. reimbursement is translating into stronger provider economics and broader access, driving higher procedure volumes.
As a result, we are raising full year 2026 epilepsy revenue growth outlook to 8%-9%, up from 7%-8% previously. In summary, our third quarter performance reflects the strength of growth drivers across our portfolio, including the ongoing Essenz upgrade cycle and continued oxygenator market share gains in cardiopulmonary, as well as favorable U.S. reimbursement dynamics and growing clinical evidence supporting VNS Therapy in epilepsy. We expect these trends to continue supporting sustainable growth while positioning us to advance our OSA strategy. As a result, we are now guiding full year 2026 revenue growth between 9%-10%, up from 8%-9% previously. Alex will provide additional details on our 2026 guidance later in the call. With that, I will hand the call over to Ahmet to cover key innovation updates across the portfolio.
Thank you, Vlad. LivaNova's innovation engine continues to drive growth today while building the foundation for sustained long-term value creation. Starting with cardiopulmonary, we are excited to announce that the new dedicated manufacturing line for LivaNova's oxygenators is now live and operational. The new line will increase output for this critical product, where demand continues to outpace supply. Combined with the additional component supply unlocked from the Thermo Fisher agreement, we are accelerating production of this life-saving product to better serve our customers and patients and are eager to ramp up further. Turning to the next-generation oxygenator, we are now in the design verification and validation phase of product development. As a reminder, our next-generation product will have its own dedicated manufacturing line, separate from and incremental to the line supporting our current-generation product.
The next-gen oxygenator is designed to deliver best-in-class performance through enhanced gas transfer efficiency, low pressure drop, and strong platelet preservation, helping reduce blood trauma and supporting better patient outcomes. We believe these attributes represent important advancement in oxygenator technology, with launch still expected in 2028. In epilepsy, the journal Neuromodulation recently published the full 36-month results from CORE-VNS, the largest prospective, multinational, real-world study of VNS Therapy devices in people with drug-resistant epilepsy, or DRE. Across more than 60 sites in 16 countries and over 800 patients, the study showed a 76% median reduction in seizure frequency at three years, with 64% of participants achieving at least a 50% reduction and nearly half seeing a reduction of 80% or more. Benefits appeared as early as three months after implantation, were sustained through 36 months, and continued to improve over time.
The study also showed meaningful improvements beyond seizure reduction, including better quality of life, less use of rescue medication, and a 73% reduction in seizure-related hospital stays. This evidence reinforces the durability of VNS Therapy in managing DRE and continues to demonstrate the benefits of VNS Therapy as a less invasive treatment option with strong efficacy for patients. Additionally, the limited market release of our cloud-based clinician portal and application continues to progress well, with excellent clinician feedback and a high engagement from early users. Physicians have used this technology with more than 1,000 patients to date. The digital health platform is already delivering meaningful workflow and connectivity benefits for patients and clinicians while establishing the foundation for future capabilities, including remote titration enabled by our next-generation IPG platform. As a reminder, the next-generation IPG and digital health platform market release are both expected in 2027.
Turning to OSA, we continue to advance our next-generation platform, which adds digital features and utilizes our PolySync algorithm. This device is designed to support a strong competitive entry and a commercial launch. We are pleased with how design verification and validation have progressed. We are confident in the previously communicated timeline for PMA supplement submission and look forward to updating you once we have submitted. As we prepare to launch, we continue to strengthen the clinical evidence supporting pHGNS, highlighted by multiple presentations at the International Surgical Sleep Society, or ISSS, and American Academy of Otolaryngology meetings in October. Notably, a new subgroup analysis from the OSPREY randomized control trial earned first place poster honors at ISSS and demonstrated consistent clinically meaningful benefit across all patient subgroups evaluated, including those with severe OSA, elevated BMI, high hypoxic burden, and higher predicted risk of complete concentric collapse, or CCC.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
